Ignite Creation Date:
2024-05-05 @ 4:40 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00291759
Status:
COMPLETED
Last Update Posted:
2013-01-30
First Post:
2006-02-13
Brief Title:
ABCSG 8 - Adjuvant Treatment in Patients With Hormone Receptor-positive Breast Cancer With Good to Moderate Differentiation
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Study Overview
Official Title:
Adjuvant Endocrine Therapy in Postmenopausal Patients With HR ve BC With Good to Moderate Differentiation - ARNO Arimidex Nolvadex Primary Treatment for 2 Years With Tamoxifen Thereafter Randomisation to Tamoxifen 3 Years or Anastrozole 3 Years
Status:
COMPLETED
Status Verified Date:
2013-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to assess the difference in event-free survival between postmenopausal women with hormone receptor-positive early breast cancer who switched from tamoxifen to anastrozole and those who continued to receive tamoxifen
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| ABCSG 8 | None | None | None |